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Therapeutic hypothermia is an effective cytoprotectant and promising intervention shown to improve outcome in
patients following cardiac arrest and neonatal hypoxia-ischemia. However, despite our clinical and experimental
experiences, the protective molecular mechanisms of therapeutic hypothermia remain to be elucidated. Therefore,
in this brief overview we discuss both the clinical evidence and molecular mechanisms of therapeutic hypothermia
in order to provide further insights into this promising intervention.
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Clinicians have investigated the application of thera-
peutic hypothermia on the human body for centuries.
Increasing clinical evidence from meta-analysis of large
randomized controlled trials and experimental data ad-
vocates the induction of therapeutic hypothermia as a
tool to achieve neuroprotection [1]. Clinical indications
for therapeutic hypothermia as a protection strategy in-
clude: myocardial infarction [2,3], cardiopulmonary by-
pass in adults [4], pediatric open heart surgery [5,6],
stroke [7], neonatal hypoxia-ischemia [8-10], and trau-
matic brain injury [11,12].
To date, the strongest evidence for its efficacy exists for
various clinical situations following cardiac arrest and neo-
natal hypoxia-ischemia. However, the effective application
of hypothermia requires a thorough understanding of the
injury mechanisms as well as its protective mechanisms.
Therefore, we discuss in this brief overview both the clin-
ical factors and molecular mechanisms of therapeutic
hypothermia in order to provide further insights into this
promising intervention.
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Therapeutic hypothermia: clinical evidence
Early experiences with therapeutic hypothermia in the
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mands [13]. Therefore, patients were routinely subjected to
deep hypothermia (<30°C) with varying durations ranging
from 2 to 10 days [14]. Animal experiments in the 1980s
led to the breakthrough discovery that using mild to mod-
erate hypothermia (31°C to 35°C) resulted in improved
neurological outcome with fewer and less severe side effects
[15]. More importantly, these findings led to the realization
that hypothermia-induced neuroprotection is not only lim-
ited to decreased oxygen and glucose demands, but the
mechanisms involved are indeed much more intricate.
Three large multicenter randomized studies of newborn
infants with hypoxic ischemic encephalopathy suggest a
beneficial effect in this patient population. Gluckman et al.
demonstrated an improved outcome that persisted at 18
months of life in term infants suffering from moderate
neonatal encephalopathy who were subjected to head
cooling (CoolCap, Natus, San Carlos, CA, USA) for 72 h
[10]. A second trial demonstrated whole-body cooling to
33.5°C for 72 h reduced the risk of mortality or moderate
to severe disability in infants with moderate or severe en-
cephalopathy surveyed at 18 to 22 months of age [16]. A
third published Total Body Hypothermia for Neonatal
Encephalopathy (TOBY) trial also showed benefits from
similar whole-body cooling in newborns with perinatal as-
phyxia [17]. The study showed that hypothermia did not
significantly reduce the rate of mortality or severe disabil-
ity but resulted in improved neurologic outcomes in in-
fants assessed at 18 months of age. However, the criteria
for optimal candidates for therapeutic hypothermia havean open access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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months of age) to assess the persistent and lifelong bene-
fits are needed.
Current investigations also include the Infant Cooling
Evaluation (ICE) trial to investigate the effect of moderate
whole-body hypothermia to 33.5°C for 72 h in newborns
with HIE [18] and the Therapeutic Hypothermia after
Pediatric Cardiac Arrest (THAPCA) trials, a 30-site ran-
domized clinical trial investigating the effectiveness of
therapeutic hypothermia versus therapeutic normother-
mia after in-hospital (THAPCA-IH) or out-of-hospital
(THAPCA-OH) cardiac arrest in children [19,20].
Clinical issues
Clinical issues regarding optimal target temperature, rate
of cooling, duration of cooling, rate of rewarming, as well
as optimal treatment window need further investigation.
With the introduction of therapeutic hypothermia, it is
important to differentiate between the ‘induction phase’ ,
when the temperature drops; the ‘maintenance phase’ ,
when the target temperature is achieved and maintained
at the desired level; and the ‘rewarming phase’ , when the
patient is slowly rewarmed back to normothermia.
Hypothermia induces stress responses, such as shivering,
that result in increased oxygen consumption and metabolic
rate in non-sedated patients. Animal experiments suggest
that the neuroprotective effects of hypothermia are negated
if cooling is used on non-sedated animals [21,22]. Other
side effects include increased risk of infection, cold diuresis
and hypovolemia, electrolyte disorders, insulin resistance,
impaired drug clearance, and mild coagulopathy [15].
Therapeutic hypothermia: molecular mechanisms
Therapeutic hypothermia-induced cellular protection
against anoxic brain injury is a global process affecting
multiple molecular and cellular mechanisms. Cooling re-
sults in a 6% to 10% decrease in cerebral metabolism for
every 1°C reduction in body temperature [23]. Therefore,
a thorough understanding of the underlying mechanisms
of protection induced by therapeutic hypothermia is vital
for designing appropriate and effective treatments. Insuf-
ficient knowledge of the physiological changes and side
effects that occur during mild (34°C to 35.9°C), mode-
rate (32°C to 33.9°C), moderate-deep (30°C to 31.9°C),
and deep (<30°C) hypothermia is likely to lead to lower
therapeutic efficacy or even failure of treatment [15].
Ischemic brain injury, reperfusion injury, and secondary
brain damage are the three main categories of temperature-
dependent injury processes that can be effectively mitigated
by mild to moderate hypothermia. Due to the broad effects
of hypothermia, it is more clinically effective than treat-
ments that focus on blocking just one of these processes.
Variable factors such as type of injury (traumatic versus
pure ischemia) and patient physiology (genetic factors,age, gender, etc.) all contribute to the complicated injury
processes. Although the window of opportunity to initiate
hypothermic treatment as well as the duration of cooling
to achieve full efficacy may vary, the success or failure of
therapeutic hypothermia treatment is dependent on the
following four key factors [24,15]:
1. Rate of cooling - rapid initiation of cooling immediately
after injury resulted in better outcomes in animal
studies. A concept summarized by the phrase
‘time is brain’.
2. Duration of cooling - dependent of severity of injury
and the time allotted to achieve target temperature.
3. Rate of rewarming - slow rewarming is critical to
not reactivate initial injury processes.
4. Management and prevention of side effects.
Apoptosis and mitochondrial dysfunction
Ischemia/reperfusion injuries can lead to cellular necro-
sis or apoptosis, also referred to as programmed cell
death. The development of apoptosis is dependent on
several cellular processes, including mitochondria dys-
function, activation of caspase enzymes, and other cellu-
lar energy metabolism disorders. Hypothermia has been
observed to affect almost all of these injury processes,
thereby preventing the initiation or interrupting the
early stages of the apoptotic pathway [25]. The window
of opportunity to initiate therapeutic hypothermia to
mitigate apoptosis after anoxia is broad, as apoptosis be-
gins relatively late and continues for a long duration.
Therefore, mitigating the effects of these injury pro-
cesses of the apoptotic pathway is a viable treatment for
neuroprotection in patients.
Interrupted blood supply to the brain causes an immedi-
ate reduction in ATP and phosphocreatine, initiating a
switch in intracellular metabolism to anaerobic glycolysis
[26]. As a result, intracellular levels of inorganic phos-
phate, lactate, and H+ are dramatically increased, leading
to both intracellular and extracellular acidosis and calcium
(Ca2+) influx into the cells [27]. To further exacerbate the
injury process, acidosis and the lack of ATP inhibit cellular
mechanisms normally responsible for controlling exces-
sive intracellular Ca2+, such as ATP-dependent Na+/K+
pumps and Na+, K+, and Ca+ channels [28]. The excess in-
flux of Ca2+ eventually leads to mitochondria dysfunction
and activation of the caspase-9 intrinsic apoptotic path-
way. Data from experimental studies have proven that
hypothermia has a beneficial impact on the ion pump dys-
function and reduces the influx of calcium into the cells,
thereby decreasing neurotoxicity [28,29].
Inflammation
Ischemia/reperfusion injury stimulates innate immune
responses, which can lead to secondary brain injury. It
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IL-1β, TNFα, and IL-6) [30], the chemokine MCP1 [31]
and pro-inflammatory mediators (ROS and NOS) in
microglia, and circulating leukocytes [32]. Hypothermia
attenuates many aspects of this pro-inflammatory im-
mune response, but it also reduces the expression of
some anti-inflammatory cytokines (IL-10 and TGFβ) [33].
Animal studies showed controversial effects of hypothermia
on NF-κB, a transcription factor that plays a central role in
regulating the inflammatory responses [34-37]. Yenari et al.
showed that mild hypothermia decreased NF-κB transloca-
tion and activation in rodents [37]. In contrast to Fairchild
et al. who showed in cell culture studies after moderate
hypothermia a prolonged accumulation of NF-κB in the
nucleus. These findings were explained with a delayed
phosphorylation of IκBα, the cytosolic inhibitory protein of
NF-κB. The Janus kinase (JAK) and signal transducer and
activator of transcription pathway (STAT) is a common sig-
naling pathway used by many cytokines. Ischemia leads to a
JAK2 and STAT3 activation mediated by IL-6. Inhibiting
this pathway resulted in a decreased number of apoptotic
cells [34]. Mild hypothermia attenuates STAT3 expression
which might be a possible mechanism of hypothermia-
induced neuroprotection [38].
Blood-brain barrier disruption
Mild to moderate hypothermia has been shown to signifi-
cantly reduce blood-brain barrier disruptions following
ischemia-reperfusion injury by decreasing vascular perme-
ability, resulting in decreased edema formation [39-41].
Specifically, hypothermia suppresses the activation of
matrix metalloproteinases (MMPs) responsible for deg-
radation of the extracellular matrix while increasing the
expression of endogenous MMP inhibitors, such as metal-
loproteinase inhibitor 2 (TIMP2) [42]. As a result, the
structural proteins and cells that constitute the BBB are
preserved and the opening of water channels is prevented.
Free radical production
The inflammatory response induced by ischemia/reperfu-
sion injury usually coincides with the production of free
oxygen radicals such as superoxide (O2
−), peroxynitrite
(NO2
−), hydrogen peroxide (H2O2), and hydroxyl radicals
(OH−) [43]. The extent of free radical production follow-
ing ischemia/reperfusion is so large that protective cellular
antioxidant mechanisms are overwhelmed, resulting in
peroxidation of lipids, proteins, and nucleic acids [27]. Al-
though hypothermia cannot completely diminish free rad-
ical production in injured cells, it can significantly reduce
the amount of free radicals enough to allow for the en-
dogenous antioxidant mechanisms to mitigate the oxida-
tive damage. In addition, the suppression of free radical
production has been observed to be linearly proportional
to the decrease in temperature [28].Rescue gene RBM3
Although hypothermia reduces cellular metabolism and
down-regulates global protein synthesis in mammalian
cells, a small subset of cold-shock proteins are induced by
low temperature. RNA-binding motif protein 3 (RBM3), a
member of the glycine-rich RNA-binding protein (GRP)
family, is one of the first proteins synthesized in response
to hypothermia [44] and hypoxia [45]. Additionally, RBM3
expression is elevated in response to NMDA-type glutam-
ate receptor activation [46]. Mild hypothermia is sufficient
to induce the expression of RBM3 [44], while elevated
temperature has been shown to suppress RBM3 expression
[47]. We observed that RBM3 expression is induced by
moderate hypothermia (33.5°C) in murine organotypic hip-
pocampal slice cultures (OHSCs) and hippocampal neu-
rons (HT-22), but not by deep hypothermia (17°C) nor in
microglia cells (BV-2) at both cooling temperatures [48].
Although many studies on RBM3 have been focused
on their regulation in non-neuronal cells in response to
hypothermia and other stress factors [44], there is grow-
ing interest in their role as effectors in therapeutic
hypothermia-induced neuroprotection. RBM3 is widely
expressed during the early stages of brain development,
especially in the first to second postnatal weeks, where it
is dynamically regulated [49]. Recent studies have con-
cluded that RBM3 has anti-apoptotic functions and can
enhance cell proliferation [50]. RBM3 is induced by hyp-
oxia independent of HIF-1 [45], which itself is suppressed
by mild hypothermia [51]. Furthermore, RBM3 has been
shown to play a major role in promoting translation in
neuronal cells, and recently, RBM3 up-regulation in neur-
onal cells in response to hypothermia has been implicated
in hypothermia-induced neuroprotection [52].
Drug-induced hypothermia
Drug-induced hypothermia may serve as an alternative
to physical hypothermia, which can be technically tedi-
ous to apply and may cause serious side effects. Animal
studies have shown that hypothermia is induced by syn-
thetic cannabinoid CB1 agonists WIN55212-2 and HU-
210. Intramuscular injection of WIN55212-2 induced
rapid and prolonged hypothermia in a dose-dependent
manner in rats [53], and HU-210 was observed to be
protective against ischemic damage by reducing infarct
volumes and motor dysfunction [54]. In the same study,
HU-210 injected after ischemic onset resulted in deeper
and lengthier hypothermia.
Conclusions
Temperature management continues to play an important
role in the treatment of patients suffering from neuro-
logical injuries. Therapeutic hypothermia and it's proven
ability to attenuate post-ischemic injury represents a
quantum leap in the clinical setting [15], but more work is
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from asphyxial cardiac arrest. Additionally, the induced
hypothermic effects of cannabinoid CB1 receptor ago-
nists, WIN55212-2 and HU-210, as alternatives to or in
combination with therapeutic hypothermia also warrant
further investigation. The full beneficial effect of cooling
remains to be discovered as we optimize the process by
expanding our knowledge of the basic mechanisms, verify
the treatment windows, and improve the cooling and
monitoring devices in the coming years.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KRLS and GT contributed equally to the drafting of this manuscript. FB
edited the manuscript and gave the final approval of the version to be
published. All authors read and approved the final manuscript.
Acknowledgments
We thank Sylvia Wowro for proofreading the manuscript.
Author details
1Department of Congenital Heart Disease/Pediatric Cardiology, German Heart
Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. 2Department
of Pediatric Cardiology, Charité Universitätsmedizin Berlin, Campus
Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany.
Received: 31 March 2014 Accepted: 27 August 2014
References
1. Drury PP, Gunn ER, Bennet L, Gunn AJ (2014) Mechanisms of hypothermic
neuroprotection. Clin Perinatol 41(1):161–175. doi:10.1016/j.clp.2013.10.005
2. Holzer M, Behringer W (2008) Therapeutic hypothermia after cardiac arrest
and myocardial infarction. Best Pract Res Clin Anaesthesiol 22(4):711–728
3. Oommen SS, Menon V (2011) Hypothermia after cardiac arrest: beneficial,
but slow to be adopted. Cleve Clin J Med 78(7):441–448. doi:10.3949/
ccjm.78a.10157
4. Svensson LG, Crawford ES, Hess KR, Coselli JS, Raskin S, Shenaq SA, Safi HJ
(1993) Deep hypothermia with circulatory arrest. Determinants of stroke and
early mortality in 656 patients. J Thorac Cardiovasc Surg 106(1):19–28,
discussion 28-31
5. Bellinger DC, Wypij D, Kuban KC, Rappaport LA, Hickey PR, Wernovsky G,
Jonas RA, Newburger JW (1999) Developmental and neurological status of
children at 4 years of age after heart surgery with hypothermic circulatory
arrest or low-flow cardiopulmonary bypass. Circulation 100(5):526–532
6. International Liaison Committee on R (2005) 2005 international consensus
on cardiopulmonary resuscitation and emergency cardiovascular care
science with treatment recommendations. Part 6: paediatric basic and
advanced life support. Resuscitation 67(2–3):271–291. doi:10.1016/j.
resuscitation.2005.09.020
7. Maier CM, Ahern K, Cheng ML, Lee JE, Yenari MA, Steinberg GK (1998)
Optimal depth and duration of mild hypothermia in a focal model of
transient cerebral ischemia: effects on neurologic outcome, infarct size,
apoptosis, and inflammation. Stroke 29(10):2171–2180
8. Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA,
Horgan MJ, Languani S, Bhatia JJ, Givelichian LM, Sankaran K, Yager JY
(2005) Moderate hypothermia in neonatal encephalopathy: efficacy
outcomes. Pediatr Neurol 32(1):11–17. doi:10.1016/j.
pediatrneurol.2004.06.014
9. Edwards AD, Azzopardi DV (2006) Therapeutic hypothermia following
perinatal asphyxia. Arch Dis Child Fetal Neonatal Ed 91(2):F127–F131.
doi:10.1136/adc.2005.071787
10. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM,
Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ (2005) Selective
head cooling with mild systemic hypothermia after neonatalencephalopathy: multicentre randomised trial. Lancet 365(9460):663–670.
doi:10.1016/S0140-6736(05)17946-X
11. Marion DW, Penrod LE, Kelsey SF, Obrist WD, Kochanek PM, Palmer AM,
Wisniewski SR, DeKosky ST (1997) Treatment of traumatic brain injury with
moderate hypothermia. N Engl J Med 336(8):540–546. doi:10.1056/
NEJM199702203360803
12. Li P, Yang C (2014) Moderate hypothermia treatment in adult patients with
severe traumatic brain injury: a meta-analysis. Brain Inj 28(8):1036–1041.
doi:10.3109/02699052.2014.910609
13. Fay T (1959) Early experiences with local and generalized refrigeration of
the human brain. J Neurosurg 16(3):239–259. doi:10.3171/jns.1959.16.3.0239,
discussion 259-260
14. Shulman K, Rosomoff HL (1959) Effect of hypothermia on mortality in
experimental injury to the brain. Am J Surg 98:704–705
15. Polderman KH (2009) Mechanisms of action, physiological effects, and
complications of hypothermia. Crit Care Med 37(7 Suppl):S186–S202.
doi:10.1097/CCM.0b013e3181aa5241
16. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan
EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara
S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH,
National Institute of Child H, Human Development Neonatal Research N
(2005) Whole-body hypothermia for neonates with hypoxic-ischemic
encephalopathy. N Engl J Med 353(15):1574–1584. doi:10.1056/
NEJMcps050929
17. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E,
Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A,
Brocklehurst P, Group TS (2009) Moderate hypothermia to treat perinatal
asphyxial encephalopathy. N Engl J Med 361(14):1349–1358. doi:10.1056/
NEJMoa0900854
18. Jacobs SE, Morley CJ, Inder TE, Stewart MJ, Smith KR, McNamara PJ, Wright
IM, Kirpalani HM, Darlow BA, Doyle LW, Infant Cooling Evaluation C (2011)
Whole-body hypothermia for term and near-term newborns with
hypoxic-ischemic encephalopathy: a randomized controlled trial. Arch
Pediatr Adolesc Med 165(8):692–700. doi:10.1001/archpediatrics.2011.43
19. Pemberton VL, Browning B, Webster A, Dean JM, Moler FW (2013)
Therapeutic hypothermia after pediatric cardiac arrest trials: the vanguard
phase experience and implications for other trials.
Pediatr Crit Care Med 14(1):19–26. doi:10.1097/PCC.0b013e31825b860b
20. Moler FW, Silverstein FS, Meert KL, Clark AE, Holubkov R, Browning B,
Slomine BS, Christensen JR, Dean JM (2013) Rationale, timeline, study
design, and protocol overview of the therapeutic hypothermia after
pediatric cardiac arrest trials. Pediatr Crit Care Med 14(7):e304–e315.
doi:10.1097/PCC.0b013e31828a863a
21. Thoresen M, Satas S, Loberg EM, Whitelaw A, Acolet D, Lindgren C, Penrice
J, Robertson N, Haug E, Steen PA (2001) Twenty-four hours of mild
hypothermia in unsedated newborn pigs starting after a severe global
hypoxic-ischemic insult is not neuroprotective. Pediatr Res 50(3):405–411.
doi:10.1203/00006450-200109000-00017
22. Tooley JR, Satas S, Porter H, Silver IA, Thoresen M (2003) Head cooling with
mild systemic hypothermia in anesthetized piglets is neuroprotective. Ann
Neurol 53(1):65–72. doi:10.1002/ana.10402
23. Hagerdal M, Harp J, Nilsson L, Siesjo BK (1975) The effect of induced
hypothermia upon oxygen consumption in the rat brain.
J Neurochem 24(2):311–316
24. Lampe JW, Becker LB (2011) State of the art in therapeutic hypothermia.
Annu Rev Med 62:79–93. doi:10.1146/annurev-med-052009-150512
25. Xu L, Yenari MA, Steinberg GK, Giffard RG (2002) Mild hypothermia reduces
apoptosis of mouse neurons in vitro early in the cascade. J Cereb Blood
Flow Metab 22(1):21–28. doi:10.1097/00004647-200201000-00003
26. Small DL, Morley P, Buchan AM (1999) Biology of ischemic cerebral cell
death. Prog Cardiovasc Dis 42(3):185–207
27. Belch JJ (1992) Free radicals and their scavenging in stroke.
Scott Med J 37(3):67–68
28. Hall ED (1997) Brain attack. Acute therapeutic interventions. Free radical
scavengers and antioxidants. Neurosurg Clin N Am 8(2):195–206
29. Siesjo BK, Bengtsson F, Grampp W, Theander S (1989) Calcium, excitotoxins,
and neuronal death in the brain. Ann N Y Acad Sci 568:234–251
30. Wang Q, Tang XN, Yenari MA (2007) The inflammatory response in stroke.
J Neuroimmunol 184(1–2):53–68. doi:10.1016/j.jneuroim.2006.11.014
31. Meybohm P, Gruenewald M, Zacharowski KD, Albrecht M, Lucius R, Fosel N,
Hensler J, Zitta K, Bein B (2010) Mild hypothermia alone or in combination
Schmitt et al. Molecular and Cellular Pediatrics 2014, 1:7 Page 5 of 5
http://www.molcellped.com/content/1/1/7with anesthetic post-conditioning reduces expression of inflammatory
cytokines in the cerebral cortex of pigs after cardiopulmonary resuscitation.
Crit Care 14(1):R21. doi:10.1186/cc8879
32. Perrone S, Szabo M, Bellieni CV, Longini M, Bango M, Kelen D, Treszl A,
Negro S, Tataranno ML, Buonocore G (2010) Whole body hypothermia and
oxidative stress in babies with hypoxic-ischemic brain injury. Pediatr Neurol
43(4):236–240. doi:10.1016/j.pediatrneurol.2010.05.009
33. Matsui T, Kakeda T (2008) IL-10 production is reduced by hypothermia but
augmented by hyperthermia in rat microglia. J Neurotrauma 25(6):709–715.
doi:10.1089/neu.2007.0482
34. Fairchild KD, Singh IS, Carter HC, Hester L, Hasday JD (2005) Hypothermia
enhances phosphorylation of I{kappa}B kinase and prolongs nuclear
localization of NF-{kappa}B in lipopolysaccharide-activated macrophages.
Am J Physiol Cell Physiol 289(5):22
35. Gibbons H, Dragunow M (2006) Microglia induce neural cell death via a
proximity-dependent mechanism involving nitric oxide. Brain Res 1084:1–15
36. Han HS, Karabiyikoglu M, Kelly S, Sobel RA, Yenari MA (2003) Mild
hypothermia inhibits nuclear factor-[kgr]B translocation in experimental
stroke. J Cereb Blood Flow Metab 23(5):589–598
37. Webster CM, Kelly S, Koike MA, Chock VY, Giffard RG, Yenari MA (2009)
Inflammation and NF[kappa]B activation is decreased by hypothermia
following global cerebral ischemia. Neurobiol Dis 33(2):301–312.
doi:10.1016/j.nbd.2008.11.001
38. Choi JS, Park J, Suk K, Moon C, Park YK, Han HS (2011) Mild hypothermia
attenuates intercellular adhesion molecule-1 induction via activation of
extracellular signal-regulated kinase-1/2 in a focal cerebral ischemia model.
Stroke Res Treat 2011:846716. doi:10.4061/2011/846716
39. Huang ZG, Xue D, Preston E, Karbalai H, Buchan AM (1999) Biphasic
opening of the blood-brain barrier following transient focal ischemia: effects
of hypothermia. Can J Neurol Sci 26(4):298–304
40. Jurkovich GJ, Pitt RM, Curreri PW, Granger DN (1988) Hypothermia prevents
increased capillary permeability following ischemia-reperfusion injury. J Surg
Res 44(5):514–521
41. Lee JE, Yoon YJ, Moseley ME, Yenari MA (2005) Reduction in levels of matrix
metalloproteinases and increased expression of tissue inhibitor of
metalloproteinase-2 in response to mild hypothermia therapy in experimental
stroke. J Neurosurg 103(2):289–297. doi:10.3171/jns.2005.103.2.0289
42. Baumann E, Preston E, Slinn J, Stanimirovic D (2009) Post-ischemic
hypothermia attenuates loss of the vascular basement membrane proteins,
agrin and SPARC, and the blood-brain barrier disruption after global
cerebral ischemia. Brain Res 1269:185–197. doi:10.1016/j.brainres.2009.02.062
43. Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD (1995) Glutamate
release and free radical production following brain injury: effects of
posttraumatic hypothermia. J Neurochem 65(4):1704–1711
44. Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, Matsuda T,
Fujita J (1997) Increased transcript level of RBM3, a member of the
glycine-rich RNA-binding protein family, in human cells in response to cold
stress. Biochem Biophys Res Commun 236(3):804–807. doi:10.1006/
bbrc.1997.7059
45. Wellmann S, Buhrer C, Moderegger E, Zelmer A, Kirschner R, Koehne P,
Fujita J, Seeger K (2004) Oxygen-regulated expression of the RNA-binding
proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci 117
(Pt 9):1785–1794. doi:10.1242/jcs.01026
46. Hsu HK, Shao PL, Tsai KL, Shih HC, Lee TY, Hsu C (2005) Gene regulation by
NMDA receptor activation in the SDN-POA neurons of male rats during
sexual development. J Mol Endocrinol 34(2):433–445. doi:10.1677/
jme.1.01601
47. Zeng Y, Kulkarni P, Inoue T, Getzenberg RH (2009) Down-regulating cold
shock protein genes impairs cancer cell survival and enhances
chemosensitivity. J Cell Biochem 107(1):179–188. doi:10.1002/jcb.22114
48. Tong G, Endersfelder S, Rosenthal LM, Wollersheim S, Sauer IM, Buhrer C,
Berger F, Schmitt KR (2013) Effects of moderate and deep hypothermia on
RNA-binding proteins RBM3 and CIRP expressions in murine hippocampal
brain slices. Brain Res 1504:74–84. doi:10.1016/j.brainres.2013.01.041
49. Pilotte J, Cunningham BA, Edelman GM, Vanderklish PW (2009)
Developmentally regulated expression of the cold-inducible RNA-binding
motif protein 3 in euthermic rat brain. Brain Res 1258:12–24.
doi:10.1016/j.brainres.2008.12.050
50. Wellmann S, Zelmer A, Nitsch C, Bucher HU, Buhrer C (2010) The Rna-
binding protein RBM3 is involved in hypothermia induced neuroprotection.
Pediatr Res 68:101–10251. Tanaka T, Wakamatsu T, Daijo H, Oda S, Kai S, Adachi T, Kizaka-Kondoh S,
Fukuda K, Hirota K (2010) Persisting mild hypothermia suppresses
hypoxia-inducible factor-1 alpha protein synthesis and hypoxia-inducible
factor-1-mediated gene expression. Am J Physiol Regul Integr Comp Physiol
298(3):R661–R671. doi:10.1152/ajpregu.00732.2009
52. Chip S, Zelmer A, Ogunshola OO, Felderhoff-Mueser U, Nitsch C, Buhrer C,
Wellmann S (2011) The RNA-binding protein RBM3 is involved in
hypothermia induced neuroprotection. Neurobiol Dis 43(2):388–396.
doi:10.1016/j.nbd.2011.04.010
53. Rawls SM, Cabassa J, Geller EB, Adler MW (2002) CB1 receptors in the
preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4
(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-
one]-induced hypothermia. J Pharmacol Exp Ther 301(3):963–968
54. Leker RR, Gai N, Mechoulam R, Ovadia H (2003) Drug-induced hypothermia
reduces ischemic damage: effects of the cannabinoid HU-210.
Stroke 34(8):2000–2006. doi:10.1161/01.STR.0000079817.68944.1E
doi:10.1186/s40348-014-0007-x
Cite this article as: Schmitt et al.: Mechanisms of hypothermia-induced
cell protection in the brain. Molecular and Cellular Pediatrics 2014 1:7.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
